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Abstract
Genes in the human leukocyte antigen (HLA) region remain the most powerful disease risk
genes in rheumatoid arthritis (RA). Several allelic variants of HLA-DRB1 genes have been
associated with RA, supporting a role for T-cell receptor-HLA-antigen interactions in the
pathologic process. Disease-associated HLA-DRB1 alleles are similar but not identical and
certain allelic variants are preferentially enriched in patient populations with defined clinical
characteristics. Also, a gene dosing effect of HLA-DRB1 alleles has been suggested by the
accumulation of patients with two RA-associated alleles, especially in patient subsets with a
severe disease course. Therefore, polymorphisms in HLA genes are being explored as tools
to dissect the clinical heterogeneity of the rheumatoid syndrome. Besides HLA
polymorphisms, other risk genes will be helpful in defining genotypic profiles correlating with
disease phenotypes. One such phenotype is the type of synovial lesion generated by the
patient. HLA genes in conjunction with other genetic determinants may predispose patients
to a certain pathway of synovial inflammation. Also, patients may or may not develop extra-
articular manifestations, which are critical in determining morbidity and mortality. HLA genes,
complemented by other RA risk genes, are likely involved in shaping the T-cell repertoire,
including the emergence of an unusual T-cell population characterized by the potential of
vascular injury, such as seen in extraarticular RA.
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Introduction
A patient is diagnosed with RA if four of seven American
College of Rheumatology criteria are satisfied [1]. Some of
these criteria are vague, particularly the key criterion of
arthritis, which is established by inspecting and palpating
joints. Interestingly, histomorphologic analysis of the
arthritic lesion is not required, which stands quite in con-
trast to other fields of medicine where tissue diagnosis is
mandatory. For outside observers, it comes as a surprise
that classification criteria, mostly relying on subjective eval-
uation, have proven to be quite useful. From a pathophysio-
logical point of view, it is inevitable that the diagnostic
category of RA includes more than a single disease entity.
Molecular genetics have now created the opportunity to
readdress this critical issue. Rheumatoid arthritis is a
classical example of a complex genetic disease character-
ized by incomplete penetrance, genetic heterogeneity and,
almost certainly, a role for multiple disease genes. In thishttp://arthritis-research.com/content/2/3/212
paper, it is proposed that differences in genetic determi-
nants and diversity of disease-risk gene combinations
generate discernible and clinically relevant variants of the
rheumatoid syndrome [2]. The current review will attempt
to utilize the knowledge of the HLA association with RA to
differentiate disease subtypes and to generate a hypothe-
sis of how different dimensions of RA could be affected by
HLA-dependent immune pathways [3].
RA — a heterogeneous syndrome
The concept that RA is a heterogeneous syndrome encom-
passing multiple disease phenotypes is supported by clinical
and pathophysiologic evidence. Clinicians have long known
that the disease course, pattern of involvement, and respon-
siveness to therapeutic interventions vary considerably [4].
Rheumatoid arthritis can take a mild expression with irre-
versible damage only appearing after decades, or bony ero-
sions can be present in early disease. Another useful
approach to dissecting disease subtypes relies on the
absence or presence of extraarticular manifestations. In pop-
ulation based studies, 56% of male patients and 42% of
female patients had clinical overt rheumatoid organ disease
[5]. Extraarticular RA shortens the life span [6]; however,
extrasynovial manifestations may only surface after a sub-
stantial lag period, emphasizing the need for predictive mole-
cular markers. The rheumatoid process can target almost
any organ. The most frequent forms of extraarticular RA,
rheumatoid nodules, are typical granulomas initiated by vas-
culopathy. Clinically, Felty’s syndrome, pulmonary disease,
ischemic heart disease, scleritis, and rheumatoid vasculitis
are more threatening, particularly when affecting medium-
sized blood vessels. Manifestations in different organ
systems can occur independently, again emphasizing the
multidimensional nature of the disease. Constitutional symp-
toms are more difficult to define; however, patients with
active disease may develop a wasting syndrome. Also,
patients with RA have an increased risk for infections [7],
and it is not known whether this reflects a genuine complica-
tion of autoimmunity or an iatrogenic component of disease.
From a pathophysiological view, the most prominent
autoimmune manifestation, the production of rheumatoid
factor (RF) autoantibodies, is only found in a subset of
patients. Such patients have more aggressive disease,
and almost all patients with extraarticular complications
are RF-positive. Whether other autoantibodies have prog-
nostic value has remained an issue of debate [8,9]. Finally,
an additional level of complexity is introduced by variability
of the synovial lesion. In a series of synovial biopsies, dif-
ferent patterns of inflammation, closely associated with dif-
ferent combinations of tissue cytokines, were identified
[10]. One third of the patients had formed follicular struc-
tures, resembling germinal centers. In 19% of the synovial
membranes, classical granulomas were found; 48% of the
biopsies revealed a type of diffuse synovitis lacking addi-
tional lymphoid microstructures.
HLA genes — one of multiple genetic factors
modulating disease risk and expression
As documented by numerous associations and recently by
genome-wide linkage studies, genes in the HLA region
play an important role in disease susceptibility [11–13].
Association studies have provided evidence that a
sequence of amino acids, termed the shared epitope, are
involved in the disease process [14]. This sequence
stretch is encountered in different alleles, bordered by dis-
tinct hypervariable regions of the HLA-DRB1 gene.
A second important feature that distinguishes the HLA
component of RA from some other HLA-associated dis-
eases is a gene dose effect [15]. Inheritance of two
copies of RA-associated HLA alleles increased disease
risk significantly. Obvious questions are whether the
context of the HLA-DRb1 chain in which the sequence
cassette is inherited, whether gene dosing influences
disease expression, and whether more than one HLA func-
tion is important in the different dimensions of the disease.
HLA molecules control a variety of functions in the immune
system. They are critically involved in restricting the recog-
nition of antigenic peptides by T cells. Considering the
dominance of T cells in the synovial lesion, it has been pro-
posed that disease-associated HLA molecules selectively
bind and present arthritogenic antigens. This model does
not satisfactorily explain the gene dose effect. Gene dosing
is compatible with a role of HLA polymorphisms in mecha-
nisms shaping the T cell repertoire [16]. Repertoire abnor-
malities have been described in RA patients. Based upon
the utilization of T cell receptor BV–BJ combinations, RA
patients can be clearly distinguished from controls [17].
Also, in RA patients, the diversity of the T cell repertoire is
contracted [18]; and large clonal expansion of CD4 [19],
as well as CD8 T cells [20], is frequently encountered.
HLA polymorphisms and the synovial lesion
Generation of synovial inflammation is almost certainly influ-
enced by HLA polymorphisms; synovitis is ultimately
dependent on T lymphocytes that regulate the production
of proinflammatory monokines and tissue-injurious metallo-
proteinases [21]. Tissue-infiltrating T cells undergo clonal
expansion in situ, with selection of identical T cells in differ-
ent joints, strongly suggesting antigen-driven T cell activa-
tion [22,23]. Finally, in rheumatoid synovitis, follicular
structures with germinal center reactions are formed.
These sophisticated lymphoid microstructures specialize in
the generation of high-affinity antibodies and are absolutely
T cell dependent [24,25]. Thus, there is overwhelming evi-
dence that immune processes in the synovium are directed
by antigen recognition. The precise nature and number of
the antigens remain to be elucidated [26].
Considering that the joint-destructive lesion reflects adap-
tive immune responses, it is a natural question whetherArthritis Research    Vol 2 No 3 Weyand and Goronzy
polymorphisms of HLA genes influence the inflammatory
reaction; specifically, whether HLA polymorphisms modu-
late the aggressiveness of rheumatoid synovitis. A series
of studies suggests that this may be the case. Retrospec-
tive studies have indicated that HLA genotyping provides
information about the aggressiveness of rheumatoid syn-
ovitis [27]. HLA-DR B1*01 alleles are preferentially found
in patients with RF-negative RA, a variant of disease
known to progress more slowly. HLA-DRB1*0404 was
enriched among RF-negative and RF-positive patients,
whereas HLA-DRB1*0401 was the dominant allele in
RF-producing patients [28]. Thus, HLA-DRB1*0401
appears to confer risk for the formation of a more rapidly
progressive synovial lesion. Patients combining
HLA-DRB1*04 and HLA-DRB1*01 required joint arthro-
plasty earlier than patients inheriting only a single copy of
RA-associated HLA alleles [15]. In prospective studies,
assessing the use of HLA typing for predicting progression
of joint disease, HLA-DRB1*04+ patients were more likely
to develop early erosive disease [29,30]. To what extent
HLA polymorphisms can be used as biomarkers to predict
disease course, however, is still unanswered [31–33]. So
far, no prospective study with sufficient patient numbers to
control for disease and treatment variables, and to assess
the impact of polymorphisms of disease-associated alleles
and gene dosing is available.
How could polymorphic HLA residues influence the char-
acter of the synovial lesion? Mechanisms of T cell reper-
toire formation, as well as local peptide selection and
presentation, could be relevant [16]. T cells utilizing
BV–BJ combinations overrepresented in the rheumatoid
repertoire are also preferentially encountered in lesional
T cells undergoing in situ proliferation [34]. Remarkably,
antigen recognition in the synovium is not uniform, but is
associated with the formation of complex lymphoid
microstructures, such as germinal centers and granulo-
mas, in subsets of patients [10]. Available data indicate
that granulomas and germinal centers do not coexist in the
same synovial sample. It is likely that HLA polymorphisms
dictate which lymphoid microstructure is formed. Possible
involvement of HLA class I molecules is suggested by the
accumulation of CD8+CD40L+ cells at the periphery of
germinal centers [35]. These CD8 cells lack expression of
perforin but carry intracellular IFNg, identifying them as
possible helper cells in the germinal center reaction.
HLA polymorphisms and repertoire
abnormalities in extraarticular RA
The highest frequencies of RA-associated HLA-DR mole-
cules are seen in patients with extraarticular RA. However,
not all shared epitope-containing alleles are equally
enriched. HLA-DRB1*01, while a risk factor for RA joint
disease, does not contribute to the risk of extraarticular
RA, whereas a combination of two HLA-DR B1*04 alleles
seems to optimize the risk [15]. The combination of
HLA-DRB1*0401 and HLA-DRB1*0404 has been
detected in patients with Felty’s syndrome [36] and
patients with rheumatoid nodules. Among patients with
rheumatoid vasculitis, individuals homozygous for
HLA-DRB1*0401 are clearly overrepresented. Studies
with sufficient numbers of patients stratified for the clinical
phenotype of extraarticular disease are required to define
the effect of different HLA polymorphisms and allelic com-
binations on the targeting of RA to different organ
systems. Preliminary evidence suggests that extraarticular
manifestations in different tissues do not have a tendency
to co-occur; for example, patients with arthritis do not nec-
essarily develop rheumatoid lung disease, and leukocyto-
clastic vasculitis manifests in a different patient subset
than rheumatoid arteritis of medium-sized arteries (unpub-
lished observations).
A second marker of abnormality in rheumatoid vasculitis is
the expansion of CD4+CD28null T cells [37]. These
unusual T cells are infrequent in healthy individuals [38];
they are expanded in RA patients, with a clear correlation
between the size of the CD4+CD28null compartment and
the clinical pattern of extraarticular disease. The inheri-
tance of two RA-associated HLA-DR alleles may facilitate
the generation of CD4+CD28null T cells.
What are the possible mechanisms through which
CD4+CD28null cells influence RA and increase the likeli-
hood of vascular complications? These cells are cytotoxic
via a granzyme/perforin mechanism [39] and produce
large quantities of IFNg [40]. A direct role of these T cells
in vascular injury is suggested by the finding that patients
with acute coronary syndrome, caused by surface rupture
of atherosclerotic plaque, also carry expanded frequencies
Figure 1
Heterogeneity of rheumatoid synovitis. Risk factors known to
predispose for particular phenotypes are listed.
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of CD4+CD28null cells [41]. In patients with fatal coronary
ischemia, CD4+CD28null cells preferentially infiltrated into
the ruptured but not the stable plaque, suggesting direct
involvement in vascular wall damage.
Summary
RA is a disease with a multitude of clinical phenotypes.
Disease heterogeneity is introduced by variations in synovi-
tis (Fig. 1) as well as diversity of extraarticular manifestations
(Fig. 2). Variability of the synovial lesion, as demonstrated by
the creation of lymphoid organizations and correlated
cytokine profiles, is likely to be regulated by differences in
T cell function, and thus is predicted to be HLA dependent.
HLA polymorphisms also have been associated with pro-
duction of RF, autoantibodies correlated with the aggres-
siveness of articular and extraarticular disease. Shared
epitope-containing DRB1*04 alleles confer risk for more
destructive synovitis with accelerated joint damage when
DRB1*04 and DRB1*01 are combined.
Combinations of two RA-associated HLA-DRB1*04
alleles mainly affect the risk for extraarticular RA. Polymor-
phic HLA genes and their combinations may have a role in
modulating the targeting of rheumatoid inflammation
outside the joint. Precise mechanisms of combined action
of HLA alleles in influencing the expression of extraarticu-
lar RA are incompletely understood, but abnormalities in
T cell repertoire formation, such as contraction of diversity
and T cell clonopathy, have been associated with vascular
injury. HLA polymorphisms may prove extremely helpful in
dissecting clinically defined phenotypes of RA, and may
thus not only have clinical impact as biomarkers, but could
also provide clues toward the different pathogenic path-
ways in the disease process.
Acknowledgments
The authors are indebted to Tammy J Dahl and James W Fulbright for their
assistance.
References
1.  Arnett FC, Edworthy SM, Bloch DA, et al: The American Rheuma-
tism Association 1987 revised criteria for the classification of
rheumatoid arthritis. Arthritis Rheum 1988, 31:315–324.
2.  Weyand CM, Klimiuk PA, Goronzy JJ: Heterogeneity of rheumatoid
arthritis: from phenotypes to genotypes. Springer Semin Immuno-
pathol 1998, 20:5–22.
3.  Weyand CM, Goronzy JJ: Pathogenesis of rheumatoid arthritis.
Med Clin North Am 1997, 81:29–55.
4.  Harris ED Jr: Rheumatoid Arthritis. Philadelphia: W.B. Saunders
Company, 1997.
5.  Weyand CM, Schmidt D, Wagner U, Goronzy JJ: The influence of
sex on the phenotype of rheumatoid arthritis. Arthritis Rheum
1998,  41:817–822.
6.  Turesson C, Jacobsson L, Bergstrom U: Extra-articular rheumatoid
arthritis: prevalence and mortality. Rheumatol (Oxford) 1999, 38:
668–674.
7. Symmons  DP:  Mortality in rheumatoid arthritis. Br J Rheumatol
1988,  27 (suppl 1):44–54.
8.  Aho K, Palusuo T, Kurki P: Marker antibodies of rheumatoid arthri-
tis: diagnostic and pathogenetic implications. Semin Arthritis
Rheum 1994,  23:379–387.
9.  Kirwan JR, Quilty B: Prognostic criteria in rheumatoid arthritis: can
we predict which patients will require specific anti-rheumatoid
treatment?  Clin Exp Rheumatol 1997, 15 (suppl 17):S15–S25.
10.  Klimiuk PA, Goronzy JJ, Bjornsson J, Beckenbaugh RD, Weyand CM:
Tissue cytokine patterns distinguish variants of rheumatoid syn-
ovitis. Am J Pathol 1997, 151:1311–1319.
11. Reveille  JD:  The genetic contribution to the pathogenesis of
rheumatoid arthritis. Curr Opin Rheumatol 1998, 10:187–200.
12.  Auger I, Roudier J: HLA-DR and the development of rheumatoid
arthritis. Autoimmunity 1997, 26:123–128.
13. Nepom  GT:  Major histocompatibility complex-directed susceptibil-
ity to rheumatoid arthritis. Adv Immunol 1998, 68:315–332.
14.  Gregersen PK, Silver J, Winchester RJ: The shared epitope hypoth-
esis. An approach to understanding the molecular genetics of
susceptibility to rheumatoid arthritis. Arthritis Rheum 1987, 30:
1205–1213.
15.  Weyand CM, Hicok KC, Conn DL, Goronzy JJ: The influence of HLA-
DRB1 genes on disease severity in rheumatoid arthritis. Ann
Intern Med 1992, 117:801–806.
16.  Goronzy JJ, Zettl A, Weyand CM: T cell receptor repertoire in
rheumatoid arthritis. Int Rev Immunol 1998, 17:339–363.
17.  Walser-Kuntz DR, Weyand CM, Weaver AJ, O’Fallon WM, Goronzy JJ:
Mechanisms underlying the formation of the T cell receptor reper-
toire in rheumatoid arthritis. Immunity 1995, 2:597–605.
18.  Wagner UG, Koetz K, Weyand CM, Goronzy JJ: Perturbation of the T
cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci USA
1998,  95:14447–14452.
19.  Schmidt D, Goronzy JJ, Weyand CM: CD4+ CD7– CD28– T cells are
expanded in rheumatoid arthritis and are characterized by autore-
activity. J Clin Invest 1996, 97:2027–2037.
20.  Fitzgerald JE, Ricalton NS, Meyer AC, et al: Analysis of clonal CD8+
T cell expansions in normal individuals and patients with rheuma-
toid arthritis. J Immunol 1995, 154:3538–3547.
21. Klimiuk PA, Yang H, Goronzy JJ, Weyand CM: Production of
cytokines and metalloproteinases in rheumatoid synovitis is T cell
dependent. Clin Immunol 1999, 90:65–78.
22.  Rittner HL, Zettl A, Jendro MC, Bartz-Bazzanella P, Goronzy JJ,
Weyand CM: Multiple mechanisms support oligoclonal T cell
expansion in rheumatoid synovitis. Mol Med 1997, 3:452–465.
23.  Ikeda Y, Masuko K, Nakai Y, et al: High frequencies of identical T
cell clonotypes in synovial tissues of rheumatoid arthritis patients
suggest the occurrence of common antigen-driven immune
responses.  Arthritis Rheum 1996, 39:446–453.
24. Tarlinton D: Germinal centers: form and function. Curr Opin
Immunol 1998,  10:245–251.
25.  Przylepa J, Himes C, Kelsoe G: Lymphocyte development and
selection in germinal centers. Curr Top Microbiol Immunol 1998,
229:85–104.
26.  Cope AP, Sonderstrup G: Evaluating candidate autoantigens in
rheumatoid arthritis. Springer Semin Immunopathol 1998, 20:23–39.
Figure 2
Phenotypic variants of extraarticular rheumatic arthritis and associated
risk factors.
Rheumatoid vasculitis
RF positive
HLA-DRB1*0401/0401
HLA-DRB1*0401/0404
Extraarticular
RA
Felty's syndrome
RF positive
HLA-DRB1*0401/0401
HLA-DRB1*0401/0404
CD4 CD28 clonotypes
+n u l l
Nodules
RF positive
HLA-DRB1*0401/0401
HLA-DRB1*0401/0404
Necrobiotic granuloma
Sicca syndrome
Female
Lung disease
Smoking
Male
CD4 CD28 clonotypes
+n u l l
CD4 CD28 clonotypes
+n u l lArthritis Research    Vol 2 No 3 Weyand and Goronzy
27.  Weyand CM, Goronzy JJ: HLA-DRB1 alleles as severity markers in
RA. Bull Rheum Dis 1994, 43:5–8.
28. Weyand CM, McCarthy TG, Goronzy JJ: Correlation between
disease phenotype and genetic heterogeneity in rheumatoid
arthritis.  J Clin Invest 1995, 95:2120–2126.
29.  Wagner U, Kaltenhauser S, Sauer H, et al: HLA markers and predic-
tion of clinical course and outcome in rheumatoid arthritis. Arthri-
tis Rheum 1997, 40:341–351.
30.  Seidl C, Koch U, Buhleier T, et al: HLA-DRB1*04 subtypes are asso-
ciated with increased inflammatory activity in early rheumatoid
arthritis.  Br J Rheumatol 1997, 36:941–944.
31.  Gough A, Faint J, Salmon M, et al: Genetic typing of patients with
inflammatory arthritis at presentation can be used to predict
outcome.  Arthritis Rheum 1994, 37:1166–1170.
32.  Suarez-Almazor ME, Tao S, Moustarah F, Russell AS, Maksymowych W:
HLA-DR1, DR4, and DRB1 disease related subtypes in rheumatoid
arthritis. Association with susceptibility but not severity in a city
wide community based study. J Rheumatol 1995, 22:2027–2033.
33.  Mottonen T, Paimela L, Leirisalo-Repo M, Kautiainen H, Ilonen J, Han-
nonen P: Only high disease activity and positive rheumatoid factor
indicate poor prognosis in patients with early rheumatoid arthritis
treated with ‘sawtooth’ strategy. Ann Rheum Dis 1998, 57:
533–539.
34.  Yang H, Rittner H, Weyand CM, Goronzy JJ: Aberrations in the
primary T-cell receptor repertoire as a predisposition for synovial
inflammation in rheumatoid arthritis. J Investig Med 1999, 47:
236–245.
35.  Wagner UG, Kurtin PJ, Wahner A, et al: The role of CD8+ CD40L+ T
cells in the formation of germinal centers in rheumatoid synovitis.
J Immunol 1998, 161:6390–6397.
36.  Wordsworth P, Pile KD, Buckely JD, et al: HLA heterozygosity con-
tributes to susceptibility to rheumatoid arthritis. Am J Hum Genet
1992, 51:585–591.
37.  Martens PB, Goronzy JJ, Schaid D, Weyand CM: Expansion of
unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis
Rheum 1997,  40:1106–1114.
38.  Vallejo AN, Nestel AR, Schirmer M, Weyand CM, Goronzy JJ: Aging-
related deficiency of CD28 expression in CD4+ T cells is associ-
ated with the loss of gene-specific nuclear factor binding activity.
J Biol Chem 1998, 273:8119–8129.
39.  Namekawa T, Wagner UG, Goronzy JJ, Weyand CM: Functional
subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum
1998,  41:2108–2116.
40.  Park W, Weyand CM, Schmidt D, Goronzy JJ: Co-stimulatory path-
ways controlling activation and peripheral tolerance of human
CD4+CD28– T cells. Eur J Immunol 1997, 27:1082–1090.
41.  Liuzzo G, Kopecky SL, Frye RL, et al: Perturbation of the T-cell
repertoire in patients with unstable angina. Circulation 1999, 100:
2135–2139.
Author’s affiliation: Cornelia M Weyand (Department of Medicine,
Mayo Clinic and Foundation, Rochester, Minnesota, USA), and Jörg J
Goronzy (Department of Rheumatology and Immunology, Mayo Clinic
and Foundation, Rochester, Minnesota, USA)
Correspondence: Cornelia M Weyand, MD, Mayo Clinic, 401
Guggenheim Building, 200 First Street SW, Rochester, MN 55905,
USA. Tel: +1 507 284 1650; fax: +1 507 284 5045;
e-mail: weyand.cornelia@mayo.edu